Drug reference

Entacapone

COMT Inhibitor · Antiparkinsonian

COMT InhibitorAntiparkinsonian

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

8 major

SEVERE in our sources

PREGNANCY

Avoid (no information available)

FDA category + note

Top interactionssee all 9 →

DextropropoxypheneSevereDatabaseDDInter
IsocarboxazidSevereDatabaseDDInter
LinezolidSevereDatabaseDDInter
Methylene BlueSevereDatabaseDDInter

Mechanism

Entacapone prevents the peripheral breakdown of levodopa by inhibiting catechol-O-methyltransferase. This action allows more levodopa to reach the brain, thereby increasing its therapeutic effect.

Indications

Adjunct to co-beneldopa or co-careldopa in Parkinson’s disease with ‘end-of-dose’ motor fluctuations (under expert supervision)Parkinson's disease (adjunct to L-DOPA)Adjunctive PD therapy given with each dose of levodopa, for "wearing-off"Used as an adjuvant to levodopa-carbidopa for advanced and fluctuating Parkinson's disease

Dosing

Adult: 200 mg by mouth, given with each dose of levodopa with dopa-decarboxylase inhibitor
Hepatic adjustment: Manufacturer advises avoid
Max dose: 2 g per day

Pharmacokinetics

Duration

2 h

Contraindications

History of neuroleptic malignant syndrome
History of non-traumatic rhabdomyolysis
Phaeochromocytoma

Side effects

Common

Abdominal painConfusionConstipationDiarrhoeaDizzinessDry mouthFallFatigueHallucinationHyperhidrosisIschaemic heart diseaseMovement disordersNauseaSleep disordersUrine discolourationVomitingorthostatic hypotensionvivid dreamshallucinationsyellow-orange discolouration of urinedyskinesiapostural hypotension

Serious